期刊文献+

新辅助化疗联合根治性子宫切除术治疗局部晚期宫颈癌的疗效及其影响因素 被引量:9

Efficacy and influencing factors of neoadjuvant chemotherapy combined with radical hysterectomy for treatment of locally advanced cervical cancer
下载PDF
导出
摘要 目的探讨新辅助化疗联合根治性子宫切除术治疗局部晚期宫颈癌(LACC)的疗效及其影响因素。方法将100例LACC患者分为观察组(新辅助化疗+根治性子宫切除术)50例,对照组(根治性子宫切除术)50例,其中新辅助化疗采用紫杉醇+顺铂方案。比较两组患者生存时间和生存率,采用Cox比例风险回归模型分析影响观察组患者3年生存率的影响因素。结果观察组、对照组中位生存期分别为43个月和37个月,观察组1、2、3年生存率分别为98.0%、90.0%、80.0%,均明显优于对照组的92.0%、78.0%、68.0%(P<0.05);单因素分析显示年龄、病灶大小、组织分化、病理类型、淋巴结转移对观察组患者3年生存率有影响(P<0.05),Cox比例风险回归模型分析显示病灶大小、组织分化、病理类型、淋巴结转移是观察组患者3年生存率的独立影响因素(P<0.05)。结论新辅助化疗联合根治性子宫切除术治疗LACC可提高患者的生存率,病灶大小、组织分化、病理类型以及淋巴结转移是其重要的预后因素。 Objective To explore the efficacy and influencing factors of neoadjuvant chemotherapy(NACT) combined with radical hysterectomy for treating locally advanced cervical cancer(LACC). Methods A hundred patients with LACC were divided into observation group treated with NACT combined with radical hysterectomy( n = 50 ) and control group treated with radical hysterectomy( n = 50). Paclitaxel and cisplatin were included in the plan of NACT. The survival time and survival rate were compared between the two groups. The factors influencing 3-year survival rate of the patients in the observation was analyzed using Cox's proportional hazards regression model. Results The median survival times of the observation group and control group were 43 months and 37 months respectively. The 1- ,2- ,3-year survival rates of the observation group were significantly higher than those in the control group(98.0% vs. 92.0% ,90.0% vs. 78.0% and 80.0% vs. 68.0%, respectively ,P 〈0. 05 ). Univariate analysis showed that age ,tumor size, histological differentiation, pathological type and lymphonode metastasis influenced the 3-year survival rate of the patients in the observation group (P 〈0.05). Cox's proportional hazards regression model analysis showed that tumor size,histological differentiation,pathological type and lymphonode metastasis were the independent prognostic factors for the 3-year survival rate of the patients in the observation group(P 〈0. 05). Conclusion For the patients with LACC, NACT combined with radical hysterectomy can increase the survival rate of the patients, and tumor size ,histological differentiation ,pathological type and lymphonode metastasis are its important prognostic factors.
作者 刘冬艳
出处 《广西医学》 CAS 2016年第9期1263-1266,共4页 Guangxi Medical Journal
关键词 宫颈癌 新辅助化疗 紫杉醇 顺铂 根治性子宫切除术 生存率 Cervical cancer Neoadjuvant chemotherapy Paclitaxel Cisplatin Radical hysterectomy Survival rate
  • 相关文献

参考文献13

  • 1Katsaros D, Gribaudo S. The proper use of multimodality treat- ment in locally advanced cervical cancer [ J ]. Gyneeol Oncol, 2011,121 (2) :422 -423.
  • 2谢辛,苟文丽主编.妇产科学[M].第8版.北京:人民卫生出版社,2013:326-328.
  • 3陈万青,张思维,郑荣寿,曾红梅,邹小农,赵平,吴良有,李光琳,赫捷.中国2009年恶性肿瘤发病和死亡分析[J].中国肿瘤,2013,22(1):2-12. 被引量:448
  • 4郑荣寿,张思维,吴良有,李光琳,赵平,赫捷,陈万青.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1):1-12. 被引量:560
  • 5Frei E. Clinical cancer research:an embattled species [ J ]. Cancer,1982,50(10) :1 979 - 1 992.
  • 6Sardi JE ,Boixadera MA,Sardi JJ. Neoadjuvant chemotherapy incervical cancer: a new trend [ J ]. Curr Opin Obstet Gynecol, 2005,17(1) :43 -47.
  • 7Malik S,Cusid6 RM,Mirjalili MH,et al. Production of the anti- cancer drug taxol in Taxus baccata suspension cultures:A re- view[ Jl. Proc Biochem,2011,46( 1 ) :23 -34.
  • 8Tajik S,Taher MA,Beitollahi H,et al. Electrochemical determi- nation of the anticancer drug taxol at a ds-DNA modified pen- cil-graphite electrode and its application as a label-free electro- chemical biosensor [ J]. Talanta ,2015,134( 1 ) :60 - 64.
  • 9Chemoradiotherapy for Cervical Cancer Meta-Analysis Collabo- ration. Reducing uncertainties about the effects of chemoradio- therapy for cervical cancer:a systenratic review and meta-analy- sis of individual patient data from 18 randomized trials [ J]. J Clin Oncol,2008,26(35) :5 802 -5 812.
  • 10Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prog- noses of pathologic stage Ib ade and squamous cell carcinoma of the uterine cervix [ J ]. Gynecol Oncol, 2000,79 (2) :289 -293.

二级参考文献41

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2朱珠,陈志明.宫颈癌Ⅰ,Ⅱ期的淋巴结转移及治疗与预后的关系——附45例临床病例分析[J].中国现代医学杂志,2004,14(23):137-138. 被引量:9
  • 3陈竺.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008:11-12.
  • 4赵平,陈万青.2008中国肿瘤登记年报[M].北京:军事医学科学出版社.2009.13—17.
  • 5Curado MP,Edwards B,Shin HR,et al.Cancer Incidencein Five Continents,Vol.Ⅸ[M].IARC Scientific Publica-tions No.160,Lyon:IARC,2008.
  • 6Parkin DM,Chen VM,Ferlay J,et al.Comparability andquality control in cancer registration[M].IARC TechnicalReport No.19,1994.
  • 7Felay J,Burkhard C,Whelan S,et al.Check and conver-sion programs for cancer registries[M].IARC TechnicalReport No.42,2005.
  • 8Felay J.The IARCcrgTools program.http://www.iacr.com.fr/iarccrgtools.htm.IACR.Lyon.2006.
  • 9全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 10Thomas G. Are we making progress in curing advanced cervical cancer? J Ctin Onco1,2011,28 : 1654-1656.

共引文献1043

同被引文献72

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部